Cargando…
Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department
The aim of the study was to evaluate the ability of a combinatorial pharmacogenomic test to predict medication blood levels and relative clinical improvements in a selected pediatric population. METHODS: This study enrolled patients between ages 3 to 18 years who presented to a pediatric emergency d...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815804/ https://www.ncbi.nlm.nih.gov/pubmed/36413430 http://dx.doi.org/10.1097/PEC.0000000000002871 |
_version_ | 1784864400042098688 |
---|---|
author | Ghosh, Pallavi Martinez, Jesse Shah, Nipam Kenan, Will Fowler, Andrew Limdi, Nita Burns, Lindsey Cogan, Elizabeth S. Gardiner, Anna Hain, Daniel Johnson, Holly Lewis, David Shelton, Richard Liebelt, Erica |
author_facet | Ghosh, Pallavi Martinez, Jesse Shah, Nipam Kenan, Will Fowler, Andrew Limdi, Nita Burns, Lindsey Cogan, Elizabeth S. Gardiner, Anna Hain, Daniel Johnson, Holly Lewis, David Shelton, Richard Liebelt, Erica |
author_sort | Ghosh, Pallavi |
collection | PubMed |
description | The aim of the study was to evaluate the ability of a combinatorial pharmacogenomic test to predict medication blood levels and relative clinical improvements in a selected pediatric population. METHODS: This study enrolled patients between ages 3 to 18 years who presented to a pediatric emergency department with acute psychiatric, behavioral, or mental health crisis and/or concerns, and had previously been prescribed psychotropic medications. Patients received combinatorial pharmacogenomic testing with medications categorized according to gene-drug interactions (GDIs); medications with a GDI were considered “incongruent,” and medications without a GDI were considered “congruent.” Blood levels for escitalopram, fluoxetine, aripiprazole, and clonidine were evaluated according to level of GDI. Relative clinical improvements in response to the prescribed psychotropic medications were measured using a parent-rated Clinical Global Impression of Improvement (CGI-I) assessment, where lower scores corresponded with greater improvement. RESULTS: Of the 100 patients enrolled, 73% reported taking ≥1 incongruent medication. There was no significant difference in CGI-I scores between patients prescribed congruent versus incongruent medications (3.37 vs 3.68, P = 0.343). Among patients who presented for depression or suicidal ideation, those prescribed congruent medications had significantly lower CGI-I scores compared with those taking incongruent medications (P = 0.036 for depression, P = 0.018 for suicidal ideation). There was a significant association between medication GDI and blood levels for aripiprazole (n = 15, P = 0.01) and escitalopram (n = 10, P = 0.01). CONCLUSIONS: Our preliminary findings suggest that combinatorial pharmacogenomic testing can predict medication blood levels and relative outcomes based on medication congruency in children presenting to an emergency department with acute psychiatric/behavioral crises. Additional studies will be needed to confirm these findings. |
format | Online Article Text |
id | pubmed-9815804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-98158042023-01-12 Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department Ghosh, Pallavi Martinez, Jesse Shah, Nipam Kenan, Will Fowler, Andrew Limdi, Nita Burns, Lindsey Cogan, Elizabeth S. Gardiner, Anna Hain, Daniel Johnson, Holly Lewis, David Shelton, Richard Liebelt, Erica Pediatr Emerg Care Original Articles The aim of the study was to evaluate the ability of a combinatorial pharmacogenomic test to predict medication blood levels and relative clinical improvements in a selected pediatric population. METHODS: This study enrolled patients between ages 3 to 18 years who presented to a pediatric emergency department with acute psychiatric, behavioral, or mental health crisis and/or concerns, and had previously been prescribed psychotropic medications. Patients received combinatorial pharmacogenomic testing with medications categorized according to gene-drug interactions (GDIs); medications with a GDI were considered “incongruent,” and medications without a GDI were considered “congruent.” Blood levels for escitalopram, fluoxetine, aripiprazole, and clonidine were evaluated according to level of GDI. Relative clinical improvements in response to the prescribed psychotropic medications were measured using a parent-rated Clinical Global Impression of Improvement (CGI-I) assessment, where lower scores corresponded with greater improvement. RESULTS: Of the 100 patients enrolled, 73% reported taking ≥1 incongruent medication. There was no significant difference in CGI-I scores between patients prescribed congruent versus incongruent medications (3.37 vs 3.68, P = 0.343). Among patients who presented for depression or suicidal ideation, those prescribed congruent medications had significantly lower CGI-I scores compared with those taking incongruent medications (P = 0.036 for depression, P = 0.018 for suicidal ideation). There was a significant association between medication GDI and blood levels for aripiprazole (n = 15, P = 0.01) and escitalopram (n = 10, P = 0.01). CONCLUSIONS: Our preliminary findings suggest that combinatorial pharmacogenomic testing can predict medication blood levels and relative outcomes based on medication congruency in children presenting to an emergency department with acute psychiatric/behavioral crises. Additional studies will be needed to confirm these findings. Lippincott Williams & Wilkins 2023-01 2022-11-22 /pmc/articles/PMC9815804/ /pubmed/36413430 http://dx.doi.org/10.1097/PEC.0000000000002871 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Articles Ghosh, Pallavi Martinez, Jesse Shah, Nipam Kenan, Will Fowler, Andrew Limdi, Nita Burns, Lindsey Cogan, Elizabeth S. Gardiner, Anna Hain, Daniel Johnson, Holly Lewis, David Shelton, Richard Liebelt, Erica Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department |
title | Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department |
title_full | Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department |
title_fullStr | Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department |
title_full_unstemmed | Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department |
title_short | Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department |
title_sort | pharmacogenomic profiling of pediatric patients on psychotropic medications in an emergency department |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815804/ https://www.ncbi.nlm.nih.gov/pubmed/36413430 http://dx.doi.org/10.1097/PEC.0000000000002871 |
work_keys_str_mv | AT ghoshpallavi pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT martinezjesse pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT shahnipam pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT kenanwill pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT fowlerandrew pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT limdinita pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT burnslindsey pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT coganelizabeths pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT gardineranna pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT haindaniel pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT johnsonholly pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT lewisdavid pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT sheltonrichard pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment AT liebelterica pharmacogenomicprofilingofpediatricpatientsonpsychotropicmedicationsinanemergencydepartment |